Christine Mikail

Biography

  Non-Executive Director Christine Mikail became a member of our board of directors in May 2017. She has over fifteen years of experience managing and advising a number of public and private biotech and pharmaceutical companies focusing in the legal and business development functions. Ms. Mikail is the founder of DCA Advisory where she is currently advising several start-up and private biotech companies. She is also an Adjunct Professor at the Rutgers Business School in New Jersey. From March 2015, to March 2017, she was Chief Administrative Officer, Head of External Business Development and Alliance Management, and General Counsel at Axovant Sciences, Inc., where she helped raise $362 million in one the largest biotech Initial Public Offerings. Prior to this, Ms. Mikail served as Senior Vice President of Legal Affairs, General Counsel and Secretary at NPS Pharmaceuticals, Inc., where she was an integral part of the deal team that sold NPS Pharma to Shire Pharmaceuticals for $5.2 billion. Ms. Mikail’s other positions included senior leadership roles at Dendreon Corporation, Savient Pharmaceuticals, ImClone Systems Corporation and later Eli Lilly, following the acquisition of ImClone. Prior to joining the pharmaceutical industry, Ms. Mikail practiced law at Reed Smith, LLP, Lowenstein Sandler PC, and Wilmer Hale. Ms. Mikail holds a Juris Doctorate from Fordham Law School and a Bachelor of Arts degree from Rutgers University.

Research Interest

Bioinformatics and system biology